This message contains images. If you don't see images, click here to view.
Advertise in this news brief.


Text version   RSS   Subscribe   Unsubscribe   Archive   Media Kit August 17, 2016    SLAS2017    Moving? New job? Let SLAS know.      




SLAS Continues to Accept Poster Abstracts for Tony B. Academic Travel Award Consideration
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
Students, post docs and junior faculty still have the opportunity to attend SLAS2017 through this SLAS program that allows up-and-coming researchers demonstrating outstanding achievement the opportunity to learn from and interact with life sciences discovery and technology community leaders.

If selected for a Tony B. Award, travel, hotel accommodations and conference registration are provided to the primary author of an accepted poster abstract for SLAS2017, Feb. 4-8, Washington, DC. Sept. 26 is the deadline to submit.

Pictured here is Joohun Kang (Wyss Institute, Harvard University), one of 60 Tony B. Award winners from SLAS2016.


SLAS Europe Council Seeks Candidates: Respond by Aug. 24
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Individuals who wish to serve on the SLAS Europe Council are invited to submit materials for consideration by midnight CET, Wednesday, Aug. 24. Nomination materials include current CV, a short statement of your reasons for seeking a position and an affidavit acknowledging your eligibility to serve.

The current SLAS Europe Council will review submitted materials and select a slate to fill three open spots on the Council; the slate will be presented to all SLAS members in the Europe Region in October. The new Council members will replace Emilio Diez-Monedero, Steve Rees and Burkhard Schaefer, whose terms expire in 2016.

Similarly, the SLAS Americas Council is seeking candidates to fill two open spots; materials for America are due by midnight CT today, Wednesday, Aug. 17.

Sponsored Content

Participate in SLAS Special Interest Group Meetings at SLAS2017
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
One of the key benefits of attending SLAS2017 is the ability to meet face-to-face with others who share your scientific interests and priorities via SLAS Special Interest Group (SIG) meetings.

Contact SIG chairs now to let them know what you'd like to talk about during these meetings, tentatively scheduled for Tuesday morning, Feb. 7, and Wednesday morning and afternoon, Feb. 8.

Welcome to RAD Source
Since 1997 Rad Source Technologies has been the expert in providing renewable, non-isotope, ionizing radiation replacements for self-shielded gamma irradiators. Currently, there are over 300 renowned hospital, university, and pharmaceutical research institutions using Rad Source X-ray technology. To find out more about our equipment, select your application and you will find equipment specifications, literature references, white papers, training videos, discussion forums, as well as other helpful info.

Headstrong Opera Debuts in Detroit
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
SLAS2017 keynote speaker Rachel Swaby calls the one-act opera written by musician Wes Fishwick the "most unexpected/delightful thing to come out of Headstrong."

The opera at the Edsel and Eleanor Ford House in Detroit explores three of the scientists featured in Swaby's book, Headstrong: 52 Women Who Changed Science and the World — Gerty Cori, Chien-Shiung Wu and Rachel Carson. Swaby speaks at SLAS2017 on Wednesday, Feb. 8, in Washington, DC.


Protein-Protein Interactions Expert and SLAS Webinar Presenter Jim Wells Speaks in New York
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
Wells of the University of California, San Francisco is one of four speakers at The New York Academy of Sciences' half-day symposium, "Protein Engineering and Protein Therapeutics," Sept. 9, from noon-4 p.m. The symposium highlights state-of-the-art technologies in protein and antibody engineering, and antibody-drug conjugates.

The implementation of these methods to specific diseases, or to develop unique research tools, is discussed. Well's SLAS Webinar, "Challenging Targets for Drug Discovery," is part of the three-part Protein-Protein Interactions as Small Molecule Drug Targets series available at SLAS On Demand to dues-paid SLAS members. Read more about Wells in the SLAS Electronic Laboratory Neighborhood e-zine.

Discover the Agilent PlateLoc Thermal Microplate Sealer

Agilent PlateLoc Thermal Microplate Sealer gives you fast, easy and reliable microplate sealing.

Sign Up for FREE E-Mail Alerts from JALA and JBS
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Be the first to know when new scientific reports publish ahead-of-print and when new issues of JALA and JBS become available by signing up for free e-mail alerts at JALA Online and JBS Online. Sign up for keyword alerts to be the first to know when new material about a particular topic becomes available.

Plus, authors whose work has been published in JALA and JBS can sign up for citation tracking alerts. All for FREE! In 2017, SLAS's two scientific journals will begin their 22nd year of publication with new names and taglines! JBS becomes SLAS Discovery (Advancing Life Sciences R&D); and JALA becomes SLAS Technology (Translating Life Sciences Innovation).
More JALA / More JBS

Sponsored Content


New Enzyme-Mapping Advance Could Help Drug Development    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Scientists at MIT and the University of São Paulo in Brazil have identified the structure of an enzyme that could be a good target for drugs combatting three diseases common in the developing world. The enzyme, fumarate hydratase (FH) is essential for metabolic processes of parasites that are responsible for the spread of three diseases: Leishmaniases, Chagas disease, and sleeping sickness. As such, understanding the enzyme's structure could help researchers figure out how to inhibit FH enzymes, thereby providing new medical therapies. More

A Faster Way to Find Medicines Hiding in Nature
Chemical & Engineering News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pharmacies are filled with molecules inspired by nature, but finding new drugs in the wide world is expensive and time consuming. Now, researchers have developed a streamlined process for identifying drug-target enzyme inhibitors and solving their molecular structures, an approach that may speed the development of new therapies. Organisms such as bacteria, plants, insects, venomous reptiles and more produce a multitude of molecules with potential medicinal activity. More

With CRISPR, Scientists Make Neurons From Fibroblasts
The Scientist    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Best known as a gene-editing tool, CRISPR has also been rejiggered to serve as a transcriptional manipulator, tuning gene activity. Duke University's Charles Gersbach and colleagues report in the September issue of Cell Stem Cell that they have used this approach to switch on three transcription factors in mouse embryonic fibroblasts and turn those cells into neurons. The method offers an alternative to the standard conversion process of bringing in these transcription factors via a viral vector. More

Novel Process for Synthesizing DNA Could Lead to Better Gene Therapies
Lab Manager    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Michigan Technological University scientists have developed a process that could lead to stickier — and better — gene therapy drugs. The drugs, called antisense DNA, are made from short, single strands of synthetic DNA. They work by blocking cells from making harmful proteins, which can cause maladies ranging from cancer to Ebola to HIV-AIDS. Only a couple of these synthetic DNA drugs are on the market, but a number are in clinical trials, including a potential treatment for ALS, also known as Lou Gehrig's disease. More

UK Scientists Get a Bit of Brexit Relief, at Least for Grant Proposals
Science Magazine    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In a move welcomed by scientists, the U.K. government has announced it will guarantee funding for research grants awarded by the European Union between now and an eventual Brexit. The decision could boost confidence for international collaborations that apply to Horizon 2020, the European Union's main competitive grants program. The decision provides "much-needed reassurance to researchers in the UK and across Europe that the UK is still in the game as a reliable player in research funding bids," said Sarah Main of the Campaign for Science and Engineering. More

Blu-ray Technology-Based Quantitative Assays for Cardiac Markers: From Disc Activation to Multiplex Detection
Analytical Chemistry    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Acute myocardial infarction (AMI) is the leading cause of mortality and morbidity globally. To reduce the number of mortalities, reliable and rapid point-of-care (POC) diagnosis of AMI is extremely critical. We herein present a Blu-ray technology-based assay platform for multiplex cardiac biomarker detection; not only off-the-shelf Blu-ray discs (BDs) were adapted as substrates to prepare standard immunoassays and DNA aptamer/antibody hybrid assays for the three key cardiac marker proteins (myoglobin, troponin I, and C-creative protein) but also an unmodified optical drive was directly employed to read the assay results digitally. More

5 Ways Bioengineers Want to Use 3-D Printing
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Now that 3-D printing has made it easier to generate custom-made prosthetics, bioengineers are looking ahead at manufacturing actual cellular material. Such technology could be the basis for personalized biomedical devices; tissue-engineered skin, cartilage, and bone; or even working bladders. In a Trends in Biotechnology special issue on biofabrication, publishing Aug. 17, researchers review and consider the progress made in 3-D bioprinting and what might be possible in the decades — or years — ahead. More

CRISPRs Point Way to New Sickle Cell Disease Therapies
Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
An international research team led by scientists at St. Jude Children's Research Hospital says it has found a way to use CRISPR gene editing to help fix sickle cell disease and β-thalassemia in blood cells isolated from patients. The study ("A Genome-Editing Strategy to Treat β-Hemoglobinopathies That Recapitulates a Mutation Associated with a Benign Genetic Condition"), which appears online in Nature Medicine, provides proof-of-principle for a new approach to treat common blood disorders by genome editing, according to the investigators. More


High-Throughput Biologics Formulation and Analysis Research Scientist
Eli Lilly and Company
US – IN – Indianapolis

Strategic Product Management Director – Fermentation/Bioreactor Technologies
Sartorius Stedim Biotech Group
Europe (choice of four locations)

Bio-Analytical Product Development Manager
Tomtec Inc.
US – CT – Hamden

Search Jobs at SLAS Career Connections


SLAS Point-to-Point
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Dennis Hall, Executive Editor, 469.420.2656   
Contribute news

This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!

SLAS Terms of Use Policy
Recent issues

Aug. 10, 2016
Aug. 3, 2016
July 27, 2016
July 20, 2016

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063